Masoud Vedadi - Toxicology

Author Information

Masoud Vedadi is a prominent researcher affiliated with the Structural Genomics Consortium at the University of Toronto, as well as the Department of Pharmacology and Toxicology at the same institution. His work is based in Toronto, Canada, where he contributes to the field of pharmacology and toxicology. His research primarily focuses on the discovery and development of small molecule inhibitors and computational methods for drug discovery, which plays a critical role in advancing biomedical research and therapeutic development.

Research Contributions

Masoud Vedadi has made significant contributions to the field of toxicology and pharmacology, particularly in the area of drug discovery. His recent works include the discovery of small molecule antagonists of human Retinoblastoma Binding Protein 4 (RBBP4) and the development of inhibitors targeting various proteins and enzymes. He has also been involved in initiatives such as CACHE (Critical Assessment of Computational Hit-finding Experiments), which aim to enhance computational methods for hit-finding, thereby advancing the field of computational chemistry. His research spans various aspects of structural biology, chemical biology, and computational hit-finding experiments, underlining his multifaceted expertise in these areas.

Aliases

Masoud Vedadi is also known by the aliases "M Vedadi" and "M. Vedadi." These variations of his name are commonly used in academic publications and citations.

Publication and Citation Metrics

Metric	Value
Total Papers	347
Total Citations	14,296
H-index	60

Publications:

Target 2035 – update on the quest for a probe for every protein

DOI: 10.1039/d1md00228g

Year: 2022

CACHE (Critical Assessment of Computational Hit-finding Experiments): A public–private partnership benchmarking initiative to enable the development of computational methods for hit-finding

DOI: 10.1038/s41570-022-00363-z

Year: 2022

Discovery of small molecule antagonists of human Retinoblastoma Binding Protein 4 (RBBP4)

DOI: 10.1101/2022.01.05.475077

Year: 2022

Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening

DOI: 10.1177/24725552211019409

Year: 2021

Pharmacological targeting of a PWWP domain demonstrates cooperative control of NSD2 localization

DOI: 10.1101/2021.03.05.433782

Year: 2021

The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors

DOI: 10.1021/acsinfecdis.1c00131

Year: 2021

The Structure-Based Design of SARS-CoV-2 Nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors

DOI: 10.26434/chemrxiv.14075408

Year: 2021

Hit identification and biochemical characterization of small molecules targeting WD-repeat domain of WDR41

DOI: 10.5281/ZENODO.4776602

Year: 2021

CACHE (Critical Assessment of Computational Hit-finding Experiments): A public-private partnership benchmarking initiative to enable the development of computational methods for hit-finding

DOI: 10.26434/chemrxiv-2021-rzq4n

Year: 2021

CACHE (Critical Assessment of Computational Hit-finding Experiments): A public-private partnership benchmarking initiative to enable the development of computational methods for hit-finding

DOI: 10.33774/chemrxiv-2021-rzq4n

Year: 2021

What is the Future of Predictive Toxicology?

What is the Role of Toxicologists in Drug Abuse Cases?

What Tools are Available for Mushroom Identification?

Who Needs Medical Monitoring?

What are Chemical Pollutants?

What is Antivenom Therapy?

How Does Identification Contribute to Public Health and Safety?

How Do Gas Detectors Work?

What Are the Health Effects of Iron Dust Exposure?

What Are the Challenges in Producing King Cobra Antivenom?

Partnered Content Networks

Relevant Topics